Abstract | Adenosine, a nucleoside derived primarily from the extracellular hydrolysis of adenine nucleotides, is a potent regulator of inflammation. Adenosine mediates its effects on inflammatory cells by engaging one or more cell-surface receptors. The expression and function of adenosine receptors on different cell types change during the course of rheumatic diseases, such as rheumatoid arthritis (RA). Targeting adenosine receptors directly for the treatment of rheumatic diseases is currently under study; however, indirect targeting of adenosine receptors by enhancing adenosine levels at inflamed sites accounts for most of the anti-inflammatory effects of methotrexate, the anchor drug for the treatment of RA. In this Review, we discuss the regulation of extracellular adenosine levels and the role of adenosine in regulating the inflammatory and immune responses in rheumatic diseases such as RA, psoriasis and other types of inflammatory arthritis. In addition, adenosine and its receptors are involved in promoting fibrous matrix production in the skin and other organs, and the role of adenosine in fibrosis and fibrosing diseases is also discussed.
Many different intercellular signals maintain homeo stasis in tissues and organs. One of the first of these signals identified in the regulation of a large num ber of physiological and pathological processes was adenosine. First identified as a potent vasodilator in 1929 by Drury and SzentGyorgi 1 , adenosine was subsequently shown to mediate its effects on cells via engagement of specific receptors (A 1 , A 2a , A 2b and A 3 (REFS 2,3)). Indeed, adenosine has been described as a 'retaliatory metabolite' (REF. 4 ) that is released from cells in response to hypoxia, metabolic stress or injury and promotes the processes required to alleviate these noxious stimuli. Among its other functions, adeno sine is an endogenous regulator of inflammation that mediates the transition from inflammation to healing. Pathological changes in, or pharmacological manipu lation of, adenosine metabolism or adenosine recep tor expression and/or function might have a role in both the pathogenesis and therapy of rheumatic dis eases. We review the metabolic changes that regulate adenosine levels in inflamed tissue, the receptors that mediate the pharmacological and pathological effects of adenosine and their role in rheumatic diseases, as well as the potential role for therapeutic targeting of adenosine and its receptors.
Adenosine in inflammation and fibrosis
Inflammation of the joints, connective tissue, mus cle and bone are the most common manifestations of the rheumatic diseases; both the innate and adaptive immune systems can contribute to the inflammation observed in diseases such as rheumatoid arthritis (RA) and psoriatic arthritis. In most inflammatory arthriti des neutrophils are the most abundant cells in synovial fluids whereas T cells, B cells and macrophages pre dominate in synovial tissues. At inflamed sites a large number of intercellular messengers and effector mole cules secreted by the various cells are present, ranging in size from low molecular weight products (such as nitric oxide and prostaglandins among many others) to proteins (cytokines, growth factors, proteolytic enzymes and others). The cells (for example, synovial fibroblastlike cells and vascular endothelial cells) of the tissues that comprise the joint also contribute to injury and destruction of the structures of the joint; osteo clasts are critical to bone destruction, and chondro cytes secrete enzymes that destroy cartilage in inflamed joints. Adenosine, acting at its receptors, regulates the activation of all of these cell types and their secretion of intercellular messengers and effector molecules of all classes.
A common end point of inflammation is fibrosis or scarring, which can disrupt the appropriate functioning of the organ affected. Thus, joint contractures are also characteristic of inflammatory arthritis, and fibrosis characterizes organs affected in extraarticular RA, such as in the lung. The major manifestations of systemic scle rosis (SSc) are fibrosis of the skin and internal organs. Adenosine and its receptors have a role in the pathogen esis of fibrosis in many different organs and might thus have a role in SSc as well.
Sources of adenosine
Intracellular ATP, the most abundant molecule in the cell, serves as the reservoir for the production of adenosine; however, most adenosine is formed in the extracellular space as a result of the sequential dephosphorylation of adenine nucleotides to adenosine (FIG. 1) . A number of transporters are involved in the export of ATP, includ ing the proteins connexin43 (also known as gap junction α1 protein) 5 , progressive ankylosis protein homologue (ANK) 6 , pannexin1 and pannexin3 (REFS 7), and prob ably others as well, including P2X7 (which is reported to affect ATP transport indirectly) 8 . Under resting condi tions some ATP is dephosphorylated to adenosine but injury, hypoxia or other metabolic assault can trigger increased rates of intracellular conversion of ATP to adenosine or, more commonly, stimulate the release of adenine nucleotides into the extracellular space where they are dephosphorylated to adenosine by ectoenzymes at the cell surface (ecto5ʹnucleotidase [CD73] and ecto nucleoside triphosphate phosphohydrolase [CD39]) and by enzymes in blood or other extracellular fluids (for example, alkaline or acid phosphatases, including tissue nonspecific alkaline phosphatase [TNAP]). Once formed or released into the extracellular space adenosine can be deaminated to inosine and, in humans, ultimately to uric acid or taken up directly by cells by specific nucleoside transporters (ENT1 and ENT2) 9 and rephosphorylated to ATP 6, [9] [10] [11] [12] [13] [14] [15] [16] (FIG. 1) .
Inflammation in the joint has long been known to lead to hypoxia due, in part, to pressure from synovial exudates, the disordered vasculature that develops in chronically inflamed synovium and the marked influx of inflammatory cells [17] [18] [19] . Although acute hypoxia leads to increased adenosine release that helps to ame liorate tissue injury following ischemia-reperfusion (reviewed elsewhere 20 ) , in settings of chronic hypoxia and inflammation the ongoing cellular injury results in mitochondrial dysfunction 21 . In addition to release of inflammatory reactants from dysfunctional mito chondria, reduced ATP production probably leads to a reduction of ATP and/or adenosine levels in extracellu lar fluid (Corciulo and Cronstein, unpublished obser vations). Despite upregulation of adenosine receptors at inflamed sites (see below) the diminished adenosine level present in chronically inflamed joints probably per mits further activation of inflammatory cells in the syn ovium 21 . Hypoxia contributes to both acute and chronic inflammation by other mechanisms as well 21 .
Adenosine receptors
Four subtypes of adenosine receptor exist, named in order of discovery: A 1 , A 2a , A 2b and A 3 . These receptors are all members of the Gproteincoupled family of 7transmembrane spanning receptors 3 (FIG. 2) . A 1 and A 2a are high affinity receptors with activity in the low to midnanomolar range whereas A 2b has a substantially lower affinity for adenosine (micromolar). Considerable speciesdependent variability in A 3 exists 22 . Adenosine receptors are widespread in their expression and are important regulators of many different types of phys iological and pathological processes. A 1 and A 3 signal via Gαi signalling proteins, which downregulate cAMP expression, whereas A 2a and A 2b are linked to Gαs pro teins, which trigger increases in cellular cAMP content. A 2b also signals through Gq proteins 23 . Expression of adenosine receptors is regulated by a number of stimuli, including inflammatory stimuli. In particular, A 2a is upregulated by agents that stimulate activation of nuclear factorκB (NFκB; a central tran scriptional regulator in the inflammatory process), such as TNF, IL1 and endotoxin [24] [25] [26] [27] [28] , and acts, as described below, as a feedback inhibitor of inflammation. Evidence from patients with RA confirms these observations: increased expression of A 2a on peripheral white blood cells in these patients is reduced by treatment with anti TNF agents 29, 30 . In addition to regulation of A 2a expres sion, TNF and other proinflammatory cytokines increase the function of these receptors by preventing receptor desensitization 31 , further down regulating inflammation. By contrast, interferonγ (IFNγ) downregulates both the expression and function of A 2a (REFS 25, 32, 33) . This downregulation (which occurs following the increase in both extracellular adenosine levels and A 2a expression and function after cellular injury or necrosis) indicates the potent role of adenosine and its receptors as feedback regulators of inflammation and innate immune responses.
Similarly, A 3 adenosine receptor expression is increased on peripheral blood white cells in patients with RA, and treatment with antiTNF antibodies reduces adenosine receptor overexpression 29, [34] [35] [36] .
Adenosine receptors and innate immunity Neutrophils
The antiinflammatory effects of adenosine were first suggested in 1983 when the capacity of extra cellular adenosine to inhibit stimulated neutrophil superox ide anion generation was demonstrated 37 , effects sub sequently confirmed and expanded upon by many others [38] [39] [40] [41] . Later studies revealed that these effects were mediated by adenosine receptor A 2a . Thus, A 2a engagement inhibits phagocytosis.
Before neutrophils can destroy invading bacteria or clear debris from a wound they must be recruited from the vasculature into the extravascular space, a process mediated by a series of adhesive interactions among neu trophils, endothelial cells and matrix. Numerous studies revealed that engagement of adenosine receptors A 2a and A 2b inhibited adhesion of neutrophils to both endothelial cells and other surfaces [45] [46] [47] [48] [49] by inhibiting both selectin and integrinmediated adhesive interactions. Interestingly, an in vitro study demonstrated that A 1 engagement enhanced neutrophil adhesion to endothelial cells via α4 integrins 48 . This same group had reported, based on studies with pharmacological inhibitors, that stimula tion of A 1 enhanced neutrophil chemotaxis 42, 50 ; however, later studies using knockout mice and their neutro phils demonstrated that, in fact, it was A 3 that mediated enhanced chemotaxis 51, 52 . One of the mechanisms by which inflammatory cell activation is terminated or downregulated is by engulfment of apoptotic cells, such as occurs at sites of crystalinduced inflammation. A 2a engagement pro motes engulfmentmediated neutrophil downregulation, whereas A 3 engagement diminishes engulfmentmediated downregulation of proinflammatory actions 53, 54 (TABLE 1) .
It has often been noted that imitation is the most sincere form of flattery and this adage is no less true for imitation of critical biological mechanisms by path ogens. Although most of the adenosine that mediates suppression of inflammation is produced endogenously, some is produced by pathogens as a virulence factor. Invasive forms of Candida albicans, Staphylococcus aureus and Streptococcus suis have all been reported to produce adenosine as a virulence factor to protect against phagocytemediated injury [55] [56] [57] . The hijacking of adenosinemediated immunosuppression by patho gens provides strong evidence for the importance of this biological mechanism.
Monocytes and macrophages
Macrophages have critical roles in initiating the innate immune response against microorganisms and in elim inating debris at sites of injury. In addition to destroying most microorganisms, macrophages produce a variety of cytokines and mediators involved in regulating inflam matory responses and present antigens to T cells in order to orient the adaptive immune response. Macrophages are antigenpresenting cells that promote the selective expansion and differentiation of lymphocytes specific for invaders or cancer cells and, in the rheumatic diseases, direct immune response to selfantigens. Two types of macrophages have been identified: M1, or classical macrophages, and M2, or alternatively activated macro phages 58, 59 . In diseases such as RA, M1 macrophages have an important role by releasing a variety of proinflamma tory cytokines (including TNF, IFNγ and IL12 among many others), as well as oxidants, nitric oxide and other smallmolecule mediators of tissue injury. M2 macro phages have a role in terminating inflammation after ingestion of apoptotic cells and promote wound healing by producing angiogenic and profibrotic cytokines.
Adenosine, acting at the A 2a receptor, suppresses production of proinflammatory cytokines and stim ulates expression of antiinflammatory mediators such as IL10 and vascular endothelial growth factor (VEGF) [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] . More generally, A 2a stimulation induces a switch from an M1 to a modified M2 phenotype 61, 70 . One mechanism by which A 2a ligation alters macrophage function is via stimulating expression of the orphan nuclear receptor NR4A, which diminishes activation of NFκBdependent gene expression 72, 73 . A 2b also stimu lates the switch from an M1 to an M2 phenotype [74] [75] [76] . The role of A 3 in regulation of inflammatory macrophage function is less clear; A 3 stimulation clearly suppresses cytokine expression and release by macrophages and diminishes inflammation in mouse models of arthritis and inflammatory bowel disease 64, 69, [77] [78] [79] [80] [81] [82] [83] [84] . Indeed, the rel atively poor antiinfective function of macrophages from human neonates is thought to reflect the dominance of A 3 expressed by these cells 79 . By contrast, studies have indicated that A 3 ligation diminishes the suppression of inflammation induced by engulfment of apoptotic cells 53 . In patients with RA, A 3 expression is a marker of disease severity and can predict the efficacy of treat ment of symptoms with a selective adenosine receptor A 3 ligand 34 (TABLE 1).
Figure 1 | Cellular adenosine production in response to hypoxia and medications.
Adenosine is produced extracellularly from the hydrolysis of adenine nucleotides (ATP, ADP and AMP) by the ectoenzymes nucleoside triphosphate phosphohydrolase (NTPP or CD39) and ecto-5ʹnucleotidase (CD73), whereas adenosine levels in the extracellular space are reduced by cellular uptake via the extracellular nucleoside transporter (Ent1) and breakdown extracellularly to inosine by adenosine deaminase. Both methotrexate and sulfasalazine diminish the activity of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase leading to accumulation of AICAR and reduction of its metabolite formyl AICAR (FAICAR). Intracellular accumulation of AICAR leads to increased ATP release into the extracellular space. Inosine monophosphate (IMP) is the final product of de novo purine biosynthesis and can be converted further to adenine and guanine nucleotides. Ultimately, much of the IMP is converted to ATP, which can be released into the extracellular space as well. Gs Gq Gi Gq A 3 Nature Reviews | Rheumatology
The effect of A 2b activation on the overall immune response remains ambiguous. As noted above, A 2b promotes a phenotypical switch from M1 to M2 mac rophages [74] [75] [76] , but also stimulates the differentiation of dendritic cells, which can promote type 17 T helper cells (T H 17) immune responses via production of IL6 . Indeed, in in vivo studies high concen trations of adenosine exacerbated arthritis and tissue destruction in rats via an A 2b mechanism 88 . Multinucleated giant cells, formed from the fusion of macrophages, are characteristic accompaniments of inflammation in response to foreign bodies or cer tain pathogens (most notably tuberculosis), and their presence in inflamed vessels gives giant cell arteritis its name. Adenosine receptors have a critical role in the formation of these syncytia as A 1 stimulation is essen tial for formation of giant cells in vitro 89 . Osteoclasts, a specialized form of multinucleated giant cell involved in bone remodelling and turnover, also depend on A 1 to complete differentiation by a mechanism involving the signalling molecule TRAF6 (TNF receptorassociated factor 6) (REFS 90, 91) . By contrast, A 2a and A 2b stimu lation inhibits osteoclast differentiation; mice lacking these receptors have osteopaenia [92] [93] [94] due, in part, to increased osteoclastmediated bone resorption. Owing to its effects on osteoclasts and macrophages and pro duction of proinflammatory cytokines, A 2a also inhibits inflammatory bone damage induced by prosthetic wear particles 95 . Interestingly, both A 2a and A 2b stimulate bone formation in vivo 96 , although only the direct stimula tory effects of A 2b on osteoblast function have been well characterized 97, 98 .
The adaptive immune system Regulation of T cells by A 2a
Effector functions of T cells in RA synovium are trig gered by the T cell receptor (TCR) recognition event fol lowed by transmembrane signalling of the TCR-CD3 complex and by multiple interconnected intracellular biochemical pathways; therefore, it is important to explore the therapeutic opportunities of targeting T cells in both hypoxic and adenosinerich microenvironments and normoxic and adenosinepoor tissue microenviron ments of inflamed joints in RA. Studies of adenosine receptors on T cells were largely motivated by the need to understand their role in antipathogen and antitu mour immunity, with a primary focus, until recently, on A 2a (REFS 99,100). The highaffinity A 2a receptor, but not A 1 or A 3 , was identified as the predominant adenosine receptor on the surface of mouse T cells 101, 102 . In view of the direct evidence for the effect of A 2a on T cells and the role of T H 17 and regulatory T (T reg ) cells in the pathogenesis of RA it would be of interest to investigate the genetic differences in ADORA2A between individual patients with RA and to search for correlations between the number of A 2a molecules per immune cell and severity of the disease. ADORA2A gene polymorphisms, as well as the number of A 2a mol ecules per immune cell, might also predispose a patient to developing RA or, equally importantly, to respond to adenosinedependent therapies such as methotrexate (see below). An interesting experimental approach to testing this hypothesis was presented in studies of func tional changes caused by genetic variation of ADORA2A that used personalized lymphoblastoid cell lines from twins as a model system 106 . This study demonstrated altered potency of a partial A 2a agonist for A 2a receptor activation in cells expressing a receptor with a previously described polymorphism associated with caffeineinduced sleep disorders.
A 2a and subsets of human T cells
Further characterization of which T cell subsets express A 2a and whether and how their functions are regulated is required, although early studies clearly demonstrated differential expression and function of this receptor on T cell subsets 107, 108 . CD4 + T helper cells express A 2a which, when stimulated by adenosine or an A 2A agonist, inhib its the proinflammatory functions of these cells 108, 109 . Similar to mouse T cells, human T helper cells increased ADORA2A mRNA levels as soon as 4 hours after activa tion, and A 2a was the predominant subtype of adenosine receptor expressed by these cells. Activation of A 2a on T cells is of great consequence not only to T cell function but also to the fate of T cells, memory T cells and Tcell homeostasis as A 2a counteracts processes leading to acti vationinduced cell death and Fas-Fasligandmediated cell death in CD4 + T lymphocytes 110 (TABLE 1) . These orig inal studies were carried out on mouse CD4 + hybridomas and human Jurkat cells (a transformed T cell line) and were subsequently expanded to in vivo studies of naive T cell development and peripheral maintenance, which is the overall outcome of extracellular signalling to T cells in different tissue microenvironments 111 . The possibility of A 2a involvement in Tcell selection processes was also the implication of early studies of immature T cells 112 .
A 2a signalling in T cells
A 2a is a Gslinked receptor that stimulates an increase in intracellular cAMP levels, which in turn activates protein kinase A (PKA). cAMP-PKA signalling directly inhibits all known TCRtriggered effector functions 102, 104 because cAMP-PKA is the 'high fidelity'
immunosuppressor that intercepts both early and late events in the TCRtriggered intracellular T cell acti vation pathway 113, 114 . Moreover, signalling mediated by A 2a , cAMP, PKA, cAMP response element (CRE) and cAMP response element binding (CREB) protein can redirect proinflammatory T cell responses toward an immunosuppressive phenotype. This change in phe notype also occurs because the extracellular adenosine accumulation driven by hypoxia and hypoxiainducible factor (HIF)1α results in hypoxia response element (HRE)dependent and CREdependent redirection of CD8, CD4 and myeloidcellmediated immune responses toward production of immunosuppressive cytokines and molecules (such as TGFβ, IL10 and CTLA4), and promotes the development of T reg cells and their inhibition of effector T cells 115, 116 . Taken together, any interpretation of the effects of adeno sine on T cells should consider A 2a signalling regu lating T cell development, maintenance and effector functions.
Regulation of T cells by A 2b
Compared with adenosine receptor A 2a , much less is known about the low affinity receptor A 2b on T cells, but -of relevance to RA -evidence indicates that activation of A 2b by synthetic agonists could have T H 17promoting effects by redirecting the differentia tion of bone marrow cells to a CD11c + GR1 + dendritic cell subset 87, 117 (TABLE 1) . Moreover, A 2b stimulation might also promote T H 17 differentiation by stimulating IL6 expression in a cAMPindependent manner 86, 117 . Others have reported that A 2b promotes T reg cell differentiation and limits inflammatory injury 118 . A 2b signals by multiple pathways; not only does A 2b increase cAMP via coupling to Gs proteins but these receptors might also signal via Gq and Gi proteins, thereby explaining their cAMP independent effects on generation of IL6 (REF. 119 ). Neutrophil Increases adhesion to matrix 48 • Inhibits superoxide anion generation [42] [43] [44] • Inhibits adhesion and recruitment • Increases engulfment-mediated downregulation of neutrophil function [45] [46] [47] [48] [49] • Unknown Chemotaxis 51, 52 Macrophage • Increases giant cell formation 89 • Increases osteoclast differentiation 90, 91 • Promotes M1 to M2 transition 61, 70 • Inhibits cytokine expression [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] • Inhibits osteoclast formation [92] [93] [94] • Inhibits osteoclast formation [92] [93] [94] • Promotes M1 to M2 transition [74] [75] [76] Inhibits cytokine expression 69, [77] [78] [79] [80] [81] [82] [83] [84] T cell Unknown • Inhibits TCR-triggered activation 101, 102 • Inhibits activation-induced cell death 110 • Inhibits Fas/FasL-mediated cell death 110 Stimulates TH17 differentiation by increasing dendritic cell IL-6 production [85] [86] [87] Unknown Endothelial cell Unknown • Increases angiogenesis 121 • Increases barrier integrity (prevents oedema) 121, 123 • Increases angiogenesis 121 • Increases oedema formation in arthritis 88 • Promotes clearance of pulmonary oedema 124 Unknown Fibroblast Unknown • Stimulates fibroblast production of collagen I and III [127] [128] [129] [130] • Promotes skin, lung and hepatic fibrosis [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] • Stimulates collagen production [127] [128] [129] [130] The effects of adenosine receptor stimulation on the formation and resolution of vascular oedema seems to vary with the tissue studied. A 2a has been reported to pro mote vascular leakage in healing wounds and inflamed sites as a result of the increase in new blood vessels that form at these sites 122 . By contrast, the barrier integrity of human umbilical vein endothelial cells is enhanced by A 2a stimulation 123 . Interestingly, A 2b stimulation pro motes clearance of pulmonary oedema 124 . A 2b stimula tion might have opposing effects in other vascular beds: excess adenosine generation, acting via A 2b , can increase inflammation and inflammatory oedema in rat mod els of arthritis 88 . Thus, targeting adenosine receptors in the prevention of angiogenesis and vascular oedema in inflammation is complex.
Similar to the effects on oedema formation and angiogenesis, the effects of adenosine and adenosine receptors on collagen and matrix production by fibro blasts and fibroblastlike cells varies from tissue to tis sue. Adenosine, acting at A 2a , directly stimulates dermal fibroblasts to produce collagen and also stimulates the production of factors, such as IL13 and connective tis sue growth factor, that are capable of further amplify ing collagen production 125 . By contrast, A 2b stimulation inhibits collagen production by some tissue fibroblasts (cardiac fibroblasts) but stimulates collagen production by fibroblasts in other tissues 125 .
Adenosine and resolution of inflammation
The inflammatory response is critical for clearance of debris and protection from invading microorganisms; inflammation sets the stage for tissue repair. As with suppression of inflammation, adenosine, acting at its receptors, promotes tissue repair and regeneration. As noted above, A 2a stimulation promotes the transfor mation of macrophages to an M2 phenotype, which is associated with lower levels of production of TNF, IL12 and other proinflammatory mediators than the M1 phenotype, and with increased production of IL10, IL13 and VEGF 58, 59 , which promote angiogenesis and fibrosis. Moreover, A 2a and A 2b stimulation promotes angiogenesis and generation of matrix by directly stim ulating endothelial cells, endothelial cell precursors and fibroblasts 121, 126 .
Adenosine receptors and fibrosis
Adenosine mediates the transition from inflamma tion to wound healing but an excess of wound healing might result in fibrosis, which can disrupt organ archi tecture and function. Fibrous contractions of the joints and fibrosis in the lungs and other tissues are common complications of RA and other rheumatic diseases, and fibrosis characterizes SSc. Results from animal models of scarring or diffuse fibrosis, a manifestation of SSc, indicate a role for adenosine and its receptors in fibro sis [127] [128] [129] [130] . Moreover, mice lacking adenosine deaminase have high levels of adenosine in the skin and sponta neously develop diffuse dermal fibrosis 128 . Elevated adenosine levels in the tissue of mice lacking adenosine deaminase also lead to pulmonary fibrosis by engaging both A 2a and A 2b (REFS 131-138) . In the liver, extracellu lar adenosine production with A 2b stimulation mediates hepatic fibrosis in mouse models, a phenomenon that is inhibited by caffeine, a nonselective adenosine receptor antagonist [139] [140] [141] . This latter finding might account for the welldocumented observation that coffee drinking and caffeine ingestion reduces deaths from liver disease [142] [143] [144] [145] [146] . Peritoneal fibrosis also depends on A 2a stimulation in animal models 147 . In the setting of priapism, in which the chronically engorged penis becomes hypoxic, aden osine release leads to both vasodilation and fibrosis via activation of A 2b (REFS 148,149). Thus, although aden osine and its receptors generally have a beneficial role in terminating inflammation, these same receptors, if persistently stimulated, lead to enhanced fibrosis with resulting tissue and organ dysfunction.
Regulation of extracellular adenosine
Under some pathological conditions tissue adenosine levels are markedly increased. Perhaps the best stud ied condition under which adenosine levels increase is hypoxia. As noted above, adenosine was first described as a coronary vasodilator in 1929 (REF. 1) and in sub sequent studies it became increasingly clear that the hyperaemic response to hypoxia was attributable, in large part, to adenosine release 150 . Presumably the breakdown of ATP and release of adenine nucleotides into the extracellular space has a role in the generation of increased extracellular adenosine; HIF1α and aden osine kinase were shown to have an important role in this pathway 151 . In addition, ENT1mediated uptake of adenosine is downregulated by increases in intra cellular cAMP 152 , and increases in extracellular adenosine drive further increases in adenosine levels by diminish ing ENT1 function via adenosinereceptormediated increases in cAMP 153 . It was recognized quite early that inflamed joints tend to be chronically hypoxic as a result of the increased cellular bulk, tissue oedema (with resulting compression of the microvasculature) and the pressure of increased synovial fluid [17] [18] [19] 154, 155 . Nonetheless, estimating the actual level of adenosine in synovial fluid is difficult as cells present in synovial fluid might undergo lysis, thus releasing ATP (which is con verted to adenosine during processing); furthermore, adenosine is hydrolysed by the adenosine deaminase present in synovial fluid [156] [157] [158] . Extracellular adenosine levels can also fluctuate in other settings. A number of drugs can regulate aden osine levels in the extracellular fluid. Most notable among these are dipyridamole and ticagrelor, which are agents that inhibit ENT1mediated adenosine uptake 153, 159, 160 . Ethanol, which is metabolized as a lipid and requires ATP hydrolysis in order to be metabolized to acetylCoA, also causes adenosine release as a result of ATP breakdown 153, [161] [162] [163] [164] . More recently, it has been appreciated that extracellular adenosine levels might reach extremely high concentrations in the setting of rapid cellular breakdown and hypoxia, such as occurs in tumours, leading to consequences such as immuno suppression by tumours 99, 100, 165 .
Therapeutic targeting of adenosine
Although no drugs have been developed to treat rheu matic diseases that directly target adenosine and its recep tors, adenosinebased targeting has been reported for a number of commonly used drugs. Antiinflammatory and antirheumatic drugs that mediate at least some of their antiinflammatory effects via targeting adenosine metabolism include methotrexate, sulfasalazine and highdose aspirin.
Methotrexate
Weekly, lowdose methotrexate remains the gold standard therapy for patients with rheumatic diseases. Although its mechanisms of action have not been fully elucidated
, it seems that enhancing adenosine release at inflamed sites has a major role in the anti inflammatory actions of lowdose methotrexate. The enzyme inhibited best by intracellular methotrexate polyglutamates is 5aminoimidazole4carboxamide ribo nucleotide (AICAR) transformylase; intracellular accumulation of AICAR leads to adenosine release 166 ( FIG. 1) . In 1991, the first results were published suggesting that methotrexate promotes adenosine release, which diminishes inflammation in vitro 167 ; it was subse quently demonstrated that adenosine mediates the anti inflammatory effects of methotrexate in an in vivo model in which increased intracellular AICAR levels at an inflamed site were documented 168 . Adenosine medi ates the antiinflammatory effects of methotrexate via occupancy of A 2a and A 3 (REF. 166 ). Moreover, adeno sine receptor antagonists, including caffeine, block the antiinflammatory effects of methotrexate treatment in an animal model of arthritis 169 and in patients with RA in prospective studies 170, 171 . A large retrospective study of patients taking methotrexate did not support the contention that caffeine ingestion reversed the anti inflammatory effects of weekly lowdose methotrex ate; however, given that patients in this study had been successfully treated for RA for a number of years, those who had not responded to methotrexate were excluded from the analysis 172 . Nonetheless, other studies pro vide further evidence for the role of adenosine in the mechanism of action of methotrexate; for example, the expression of CD39, an ectoenzyme that catalyses the dephosphorylation of ATP and ADP to AMP (which is critical for extracellular adenosine production), is a bio marker for methotrexate efficacy in patients with RA 173 . Other mechanisms of action have been described for the antiinflammatory actions of methotrexate in the treat ment of RA and other rheumatic conditions that do not include a role for adenosine 166, [174] [175] [176] .
Sulfasalazine
Sulfasalazine was first developed as a specific therapy for RA in the 1940s and remains in use today. Sulfasalazine is broken down by gut bacteria to 5aminosalicylate and sulfapyridine; sulfasalazine itself and 5aminosalicylate are poorly absorbed from the gut and sulfapyridine acts as an antifolate once absorbed. Indeed, folate deficiency is a recognized side effect of sulfasalazine 177 . Among its other effects sulfasalazine promotes accumulation of intracellular AICAR and release of adenine nucleotides into the extracellular space where they are dephospho rylated to adenosine; blockade or loss of ecto5ʹnucleoti dase prevents adenosine release induced by sulfasalazine both in vitro and in vivo and reverses the adenosine receptordependent antiinflammatory effects of the drug in a mouse model of inflammation 178, 179 (FIG. 1) .
These results suggest that, like methotrexate, adenosine mediates at least some of the antiinflammatory effects of sulfasalazine.
High-dose aspirin
Although not commonly used anymore for the treatment of RA and other rheumatic diseases, highdose aspirin was a mainstay of antirheumatic therapy until the devel opment of lesstoxic NSAIDs in the 1970s. Before the rec ognition that aspirin and other NSAIDs mediated many of their actions by inhibiting cyclooxygenases, it was thought that one mechanism by which highdose aspirin mediated its therapeutic and toxic effects was by uncou pling oxidative phosphorylation and loss of intracellu lar ATP 180, 181 . Results of studies in human neutrophils
Box 1 | Mechanisms of action of methotrexate
Methotrexate was originally developed as a folic acid antagonist to prevent the de novo synthesis of purines and pyrimidines in the treatment of cancer and leukaemia, which remain indications for use of this drug. Although high-dose aminopterin, an analogue of methotrexate, was reported to be useful in the treatment of rheumatoid arthritis (RA) in the early 1950s 187 , methotrexate was not widely used to treat inflammatory arthritis until anecdotal reports and uncontrolled trials were carried out in the 1970s followed by placebo-controlled trials in the 1980s and approval for the treatment of RA in 1989 (REF. 188 ). Although initially thought to block lymphocyte proliferation via inhibition of purine and pyrimidine synthesis, the inability of folic acid supplementation to reverse the efficacy of methotrexate treatment while preventing folate-dependent toxicities did not support this effect for methotrexate used at doses up to 1/100th of the dose given to treat malignancy [189] [190] [191] . In the treatment of RA, psoriasis and other inflammatory conditions, methotrexate is administered in low doses (5-25 mg) once per week and has a half-life that is relatively short. It is undetectable in the circulation after 18 h but is widely distributed and present in tissues as long-lived polyglutamates, which remain potent inhibitors of a number of enzymes involved in the synthesis of purines and pyrimidines. The enzyme inhibited most potently by methotrexate polyglutamates is 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase (AICART); inhibition of this enzyme leads to intracellular AICAR accumulation ( see FIG. 1 ). Increased intracellular AICAR promotes adenosine release, and blockade or deletion of adenosine receptors reverses the anti-inflammatory effects of methotrexate in animal models and patients with RA 166 .
indicated that some of the effects of highdose salicylates on stimulated neutrophil function resulted from ATP loss and extracellular conversion to adenosine 182 . Subsequent studies in mice confirmed that adenosine mediates the antiinflammatory effects of highdose aspirin in vivo as well 183 . The doses of aspirin required verge on the toxic and are almost never used at present.
Antirheumatic drugs in development
On the basis of their antiinflammatory activity in a variety of animal models 184 , A 3 agonists are currently under development for the treatment of RA. Indeed, a phase II clinical trial of CF101, an A 3 agonist, demon strated reduced RA activity although the improvement did not achieve statistical significance 185 . Interestingly, an increased clinical response to CF101 was seen in patients in whom A 3 was overexpressed on peripheral blood mononuclear cells 185 . CF101 has also been administered to patients for the treatment of psoriasis and an early phase study demonstrates clear evidence of efficacy for this indication 186 .
Conclusions
The role of adenosine and its receptors in regulating inflammation and immune responses has been well established. Adenosine, released by hypoxic or injured tissues or following treatment with drugs such as metho trexate, suppresses inflammation and immune responses via stimulation of its receptors on inflammatory and immune cells. Although this mechanism of action is use ful for the treatment of diseases such as RA, in the setting of tumours the immunosuppression that occurs might be deleterious. The conditional benefits of modulating inflammation and immunity dictate that targeting aden osine receptors with agonists or antagonists will require individual tailoring.
